|
At Kendle, we know that for each day a successful drug is not on the market, a company will lose about $1.3 million (Source: Frost & Sullivan), meaning it’s vital to get your product to market as fast as possible to ensure a return on your investment.We also know that getting your product to market in today’s marketplace is full of challenges that we can help you overcome.
During Clinical Development, for example, Phase III trials run an average of 30% longer than the pharmaceutical trial team’s original plan, and this is often due to problems finding required numbers of patients (Source: Cutting Edge Information, October 2004). At Kendle, we have the capability of creating targeted, country-specific programs to recruit and retain patients who meet your study inclusion criteria. We understand the cultural and regulatory differences in each country and can design a strategic plan based on these requirements. We deliver large Phase III programs in important therapeutic areas, such as oncology, CNS, analgesia/pain, inflammation, gastrointestinal and cardiovascular. In fact, we conducted one of the largest adjunctive oncology trials of its type.
Navigating your way through the varying regulatory requirements in different countries can also be a challenging task. You can be reassured that with Kendle, you are working with a company that can develop regulatory strategies that address both expected and unanticipated issues. We will ensure the shortest route through clinical Phases I–IV, to bring your product to market and provide the necessary expertise to ensure continued regulatory compliance.
And if you need a biometrics partner who is committed to saving you time and money, you need Kendle. At Kendle Biometrics we apply best practices that promote consistent delivery of high quality data, save money and speed up the clinical development process. Our study metrics expertise also increases our ability to assess your project and resourcing needs accurately, optimizing study outcomes.
Overall, in today’s global markets there are few new drugs in the pipeline and even fewer blockbuster drugs getting to market, so late phase development and commercialization becomes a crucial stage in every product life cycle. That’s why we look at your drug’s potential from a completely different perspective. It’s the best way to maximize your product’s scientific credibility and brand awareness.
We know that our global customers have particular needs. From first-in-human studies through market launch and surveillance, maximizing product life cycles and growing market share. Through our knowledge of the marketplace, our aim is to not only understand your needs, but to focus all our energy and resources on meeting those needs  |
